Table 3.

Intrahepatic disease response assessed using mRECIST criteria.

Response	ISP-TACE group	Sora-TACE group	P
CR	11 (22)	3 (6)
PR	18 (35)	16 (30)
SD	15 (29)	17 (31)
PD	7 (14)	18 (33)
DCR (CR+PR+SD)	44 (86)	36 (67)	0.018

Data are n (%) unless otherwise indicated.

CR, complete response; DCR, disease control rate; ISP-TACE, irradiation stent placement plus transcatheter arterial chemoembolization; mRECIST, modified Response Evaluation Criteria in Solid Tumors; PD, progressive disease; PR, partial response; SD, stable disease; Sora-TACE, sorafenib plus transcatheter arterial chemoembolization.